Blog post
Myeloma Misdiagnosis to CAR-T Remission: A Survivor’s Advocacy StoryThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
Key Takeaways from the IMF Facebook Live on Myeloma Clinical Trials On Saturday, July 19, International Myeloma Foundation (IMF) Chief Medical Officer Dr. Joseph Mikhael — along with SparkCures Founder & CEO Brian McMahon and 20-year myeloma patient and advocate Thomas Goode — hosted a…
Blog post
July and August 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage,…
Blog post
The International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will help raise awareness about the disease, inspire action…
Blog post
On Tuesday, July 1, the International Myeloma Foundation conducted its annual webinar, “Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient…
Blog post
On Tuesday, July 1, the International Myeloma Foundation conducted its annual webinar on “Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community.
…
Blog post
Myeloma Research Updates: Key Takeaways from ASCO, EHA & IMWG
Every year, three annual events that take place in quick succession hold a special significance for the researchers and clinicians working in the field of myeloma. The 2025 annual meeting of the American Society of…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
State of Myeloma 2025: New Treatments & Research
With very encouraging data and results of various myeloma research efforts unveiled at the 2025 American Society of Clinical Oncology (ASCO) annual summit in Chicago, IL, and the European Hematology Association (EHA) Congress in Milan, Italy,…
Page
Food and Nutrition Assistance for People With Multiple MyelomaBalanced nutrition is important for everyone, especially people living with multiple myeloma. However, the cost of food, changes in income, transportation barriers, and the demands of cancer treatment can make it difficult for patients…
News Article
Positive topline results from the Phase 2 QUINTESSENTIAL trial showed arlocabtagene autoleucel (arlo-cel) met the study’s primary and key secondary efficacy endpoints in patients with heavily pretreated, relapsed and refractory multiple myeloma (RRMM). On Tuesday, September 8, Bristol Myers…
Blog post
ODAC finds sufficient evidence that benefits outweigh risks; supports treating HR-SMM patients with daratumumab and hyaluronidase-fihj
On Tuesday, May 20, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) “voted (6-2) in favor of the benefit-risk…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
A Closer Look at A Study on the Global and Regional Burden of Myeloma Among Patients Aged 40 and Over
A recent study published in Scientific Reports, Trends and projections of the global and regional burden of multiple…
Blog post
Medical Student Scholar Tyra Grischke and Dr. Ben Derman talk about their collaborative study in a Q&A with the IMF
On March 28, Blood Cancer Journal published the study, “Brain-to-vein and vein-to-vein times and…
Blog post
Myeloma Experts Drs. Joseph Mikhael and Rafat Abonour Discuss the Future of Myeloma
By Joseph Mikhael MD, MEd, FRCPC, FACP, FASCO
IMF Chief Medical Officer
When I started my work in myeloma more than 20 years ago, it was truly a terrible disease, and most…
Blog post
Taking a Deeper Dive into the IMF's iStopMM Study
Principal Investigator Sigurður Yngvi Kristinsson, MD, PhD provides insights on the iStopMM Project and delves into why the ambitious research trial is headed toward finding a cure for myeloma.
If you are part of the IMF’s myeloma…
Blog post
On Saturday, March 15, IMF Chief Medical Officer Joseph Mikhael MD, MEd, FRCPC, FACP, FASCO, along with IMF Vice President of Development Sylvia Dsouza, hosted a Facebook Live Q&A session in Boca Raton, FL to answer the most pressing questions about myeloma care, myeloma research, and…
Blog post
On Thursday, March 6th, IMF Scientific Advisory Board Member, and Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center Saad Z. Usmani, MD, MBA, FACP, FASCO hosted a live Q&A session on Facebook to answer the most pressing questions about multiple myeloma as…
Blog post
The International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will help raise awareness about the…
Blog post
Prior Authorization Delays in Myeloma Care: A Patient’s Fight for RevlimidThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that…
Blog post
Bryan Soronson Advocates for Myeloma Clinical Trials
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation (IMF) is excited to share this collection of patient and care partner stories from those who have completed the first course of the Legislative…
Blog post
35 Years of Myeloma Progress at the IMF This year’s Myeloma Action Month (MAM) is especially significant for the International Myeloma Foundation. In 2025, we will be celebrating our 35th anniversary—the perfect occasion to recollect 35 years of meaningful myeloma milestones, as we look…
Blog post
A Myeloma Patient with a Mission: Coaching and Advocacy
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation is excited to share this collection of patient and care partner stories from those who have completed the first course of the…
Blog post
Mother, Wife, Scientist, Researcher, and More
Lisa Hatfield is a self-described “mom, a wife, a scientist, a researcher, a dark chocolate and book lover, and a multiple myeloma patient.”
Like many myeloma patients, Lisa’s initial diagnosis was almost missed. Lisa shares, “After experiencing…
Blog post
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation is excited to share this collection of patient and care partner stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that these…
Blog post
This week, we’re putting the spotlight on five important facts that people of African descent need to know about multiple myeloma. The International Myeloma Foundation seeks to help raise awareness about the incidence of the disease among the African American population, and to encourage…
Blog post
Diane Kennedy: A Care Partner's Journey and Passion for Advocacy
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation is excited to share this collection of patient and care partner stories from those who have completed the first course of the…
Blog post
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation is excited to share this collection of patient stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and…
Blog post
Essential Self-Care Tips for Myeloma Patients
At the International Myeloma Foundation (IMF), myeloma patients and their needs always come first. One of the most important aspects of living with multiple myeloma is self-care—not just for patients, but also for care partners. …
Blog post
What Myeloma Patients Should Know About Pomalyst and Medicare Price Negotiations
The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) recently announced the selection of an additional 15 drugs for Medicare Part D price negotiations,…
Blog post
Essential Emergency Preparedness for Wildfires
(Editor’s Note: The International Myeloma Foundation has offered its Los Angeles headquarters in Studio City, CA as a temporary shipping location for life-saving medications and treatments for myeloma patients who have been displaced and…
Blog post
On Monday, December 8, IMF Chief Medical Officer Dr. Joseph Mikhael, along with IMF Vice President of Patient Support and 24-year myeloma care partner Robin Tuohy, IMF Support Group Leader and 24-year myeloma patient Michael Tuohy, IMF Director of Support Groups Jenn Wieworka DNP, and…
Blog post
ASH 2024 Myeloma Highlights from Patients and Support Group LeadersAs the 66th American Society of Hematology (ASH) Annual Meeting and Exposition came to a close, IMF Support Groups and the myeloma community at large gleaned new and significant insights from the latest research in the field of…
Blog post
Progress in the Field of Myeloma: the Past, the Present, and the Future
By Dr. Joseph Mikhael, IMF Chief Medical Officer
The pace of drug development and advancement in myeloma in 2024 has been truly unprecedented, with a cascade of drug approvals, innumerable…
Blog post
Key Myeloma Research Highlights from the 2024 ASH Annual Meeting
Every December, the international hematology community comes together to share the latest and greatest in research.
With an expected 35,000 attendees in San Diego this week, there is no doubt that this year’s 66th…
Blog post
When you’re managing a condition as complex as myeloma, every decision matters. Teresa Miceli, BSN, RN, OCN, with over three decades of experience in myeloma care, shared insights on the importance of shared decision-making for patients and caregivers. She emphasizes how essential it is for…
Blog post
Medigap for Multiple Myeloma Patients: A Q&A Guide With Medicare open enrollment ongoing from October 15 – December 17, 2024, the International Myeloma Foundation (IMF) aims to provide education and guidance on Medicare policies and issues that are…
Blog post
In August 2024, a team of 15 individuals (including myeloma patients, care partners, and doctors) were on a quest to finish a 100-mile expedition across Iceland to raise both awareness for the disease and funding for research aimed at finding a cure.
By…
Blog post
Myeloma Nurse Q&A on Vaccines, Monitoring, and Early Detection IMF NLB experts share insights on early myeloma detection, treatment, and support. As part of the International Myeloma Foundation’s efforts on raising awareness for multiple myeloma during Blood Cancer Awareness…
Blog post
At the culmination of the 8th Annual Asian Myeloma Network Summit in Seoul on Sunday, October 20, there were invaluable gems that attendees took with them from this year’s largest gathering of myeloma specialists, patients, and caregivers in Asia.
Here are some of…
Blog post
Blenrep for Myeloma: Uses, Side Effects & Status
What Is Blenrep (belatanmab mafodotin) and How Does It Work?
Blenrep® (belantamab mafodotin) is a monoclonal antibody that targets B-cell maturation antigen (BCMA)…
Blog post
When we think about planning, we usually think about big life events—weddings, having a baby, or saving for college. But have you ever thought about planning for your healthcare, especially if you couldn’t speak for yourself? It might sound intimidating, but advanced care planning is simply about…
Blog post
How the IMF Helps Multiple Myeloma Patients Thrive The International Myeloma Foundation (IMF) is the world’s premier myeloma resource for patients. I am one of those patients. Thirteen years ago, I was diagnosed completely by accident in July 2011. I am grateful and blessed to be able to write…
Blog post
Andreas Kakarougkas, PhD, is an Assistant Professor of Cell and Molecular Biology and Director, of Biotechnology Graduate Program at the Department of Biology in the School of Sciences and Engineering at the American University in Cairo. Dr. Andreas was so moved by this year’s Blood Cancer…
Blog post
This week’s blog was adapted from a presentation given by Danielle Doheny, the Director of Public Policy and Advocacy for the International Myeloma Foundation (IMF), at the IMF’s Patient and Family Seminar in Los Angeles in August 2024.
You may have wondered what IMF advocacy team…
Blog post
Building a Support NetworkAs a nurse and a member of the IMF’s Nurse Leadership Board, I would like to provide you with some insight on how to build a support network as you navigate multiple myeloma.What Is a Support Network?A support network is simply a group of people that can assist you during…